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concerning varicella zoster-associated progressive outer retinal necrosis (PORN) after allogeneic stem cell transplantation, and describe another, similar case. The patient is currently alive and well, although with profound visual impairment.
A 51-year-old man was diagnosed with refractory anaemia with excess blasts type one (RAEB 1) and treated with two cycles of FLAG-Ida chemotherapy. Bone marrow examination showed remission (o5% blasts) but persistent dysplasia. He then underwent a reduced intensity conditioned matched unrelated donor stem cell transplant using fludarabine, melphalan and Campath I-H as conditioning. He received bone marrow stem cells from a male donor, with a low CD34 count of approximately 1 Â 10 6 /kg recipient body weight. Immunosuppression was with cyclosporine, commenced on day À1.
By day þ 22 from conditioning, he had a total WBC of 0.8 Â 10 9 /l with 500 neutrophils, although he remained platelet transfusion dependent until day þ 54, and lymphopenic until some 10 months post transplant. A bone marrow aspirate taken 2 months post transplant showed dysplasia but no excess of blasts, and 100% donor chimerism.
At 4 months post transplant, he developed Varicella ZosterVirus (VZV) infection affecting the right T6 dermatome despite the fact that he had been taking prophylactic aciclovir, 200 mg three times a day. The dose of acyclovir was increased to 800 mg five times a day for 2 weeks and then 400 mg five times a day for 1 week. He had a good response and was recommenced on a prophylactic dose of 200 mg acyclovir three times a day in view of his on-going lymphopenia and immunosuppression. After 2 weeks there was a recrudescence of the varicella zoster, and he was restarted on aciclovir 800 mg five times a day for 1 week orally, followed by a continued dose of 400 mg five times a day. The skin eruptions resolved. During this period, plasma samples for qualitative VZV PCR were strongly positive, although levels were not quantitated.
At 7 months post transplant, while still receiving cyclosporine, he became increasingly dyspnoeic. Bilateral reticulonodular shadows were present on chest X-ray, and a CT scan showed bronchiectasis and peripheral fibrosis. He was commenced on broad spectrum intravenous (i.v.) antibiotics, and in view of the recent zoster infection he received high-dose i.v. acyclovir for 2 weeks. Bronchoscopy and lavage revealed no abnormalities and a clinical diagnosis of lung graft-versus-host disease was made. Prednisolone 1 mg/kg was started, and antiviral therapy with oral valaciclovir 1 g three times a day was continued as the zoster lesions had not completely resolved. Mycophenolate mofetil was commenced in addition to cyclosporin when the steroid dose was reduced, in view of the diagnosis of probable lung graft-versus-host disease and the fact that he was still suffering from significant shortness of breath.
After 1 month, he presented with a 5-day history of a left visual field defect. Opthalmologic review confirmed concentric constriction of the left visual field, a left afferent papillary defect and visual acuity of 6/9 bilaterally with near vision N5. The left fundus showed extensive peripheral pigmented mottling with a small, isolated haemorrhage while the right showed more localised and less marked change. Both discs and maculae were healthy. A diagnosis of bilateral acute retinal necrosis secondary to varicella zoster was made. A CT scan of the brain excluded haemorrhage, and MRI scans of the brain and orbits were normal.
He continued on oral valaciclovir, and was referred to a specialised retinal unit where the possibility of additional old inflammatory changes was considered and a differential diagnosis of cytomegalovirus (CMV) was suggested. It was noted, however, that he was at low risk of CMV infection as both he and his stem cell donor had tested negative prior to the transplant, he always received CMV-negative blood products and CMV PCR levels had remained negative throughout the post transplant period.
Systemic therapy with foscarnet was commenced to cover both CMV and VZV, and the dose of prednisolone was increased to 40 mg/day. After 2 weeks of i.v. foscarnet, there was a deterioration in the vision of both eyes. The left eye showed loss of light perception and retinal detachment. The right showed acute deterioration of acuity from 6/6 to 6/60 over 3 days and additional swelling of optic disc and macular involvement (Figures 1 and 2) . At this stage a diagnosis of bilateral progressive outer retinal necrosis (PORN) was made and VZV infection was confirmed by PCR on vitreal biopsy material. CMV and herpes simplex (HSV1, HSV2) were not detected. Throughout this period, qualitative plasma PCR studies continued to show strong positivity on banding.
Therapy was altered in an effort to preserve the remaining vision. I.v. foscarnet was changed to i.v. ganciclovir and he was additionally started on i.v. cidofovir fortnightly with close monitoring of renal function. He was also started on intravitreal foscarnet injections twice weekly and given one dose of human immunoglobulin, 0.4 gm/kg.
He was subsequently discharged taking oral valacyclovir 1 g three times daily and continues under regular review. Plasma PCR for VZV now showed only weak positivity.
He describes progressive dimming of his vision which he likens to the illumination provided by light bulbs of increasingly low Wattage. He can currently see only large shapes in shades of grey with no colour, but feels that his vision has now stabilised.
This case further highlights an unusual complication of stem cell transplantation, which needs aggressive investigation and combination therapy in order to maximise the chances of conserving as much vision as possible. Although in the present case visual deterioration progressed even after plasma VZ DNA levels had fallen and in spite of several changes in antiviral therapy, it remains to be seen whether the newer antiviral agents will improve outcome in this difficult situation and whether careful monitoring of plasma viral load in relation to the antiviral medication being administered will enable such visual loss to be slowed or halted. 
